# TPM3-NTRK1 Fusion Cervical Sarcoma: A Case Report of a Novel Subset of Gynaecological Sarcomas and Successful Treatment of Recurrent Disease With Trk-Inhibition Therapy

## TL;DR

A patient with a rare cervical sarcoma showed long-term remission after treatment with larotrectinib, a drug targeting NTRK gene fusions.

## Contribution

This is the first reported case of successful Trk-inhibition therapy for a TPM3-NTRK1 fusion cervical sarcoma.

## Key findings

- The patient remained stable for over three years after starting larotrectinib treatment.
- Larotrectinib effectively managed recurrent NTRK-positive cervical sarcoma after prior therapies failed.

## Abstract

Neurotrophic tyrosine kinase receptor (NTRK) activation by neurotrophins has been shown to promote cellular proliferation, differentiation, and survival by preventing apoptosis. NTRK gene fusions are rare in gynaecological cancer. This case report describes the successful management of a metastatic NTRK-positive cervical sarcoma using Trk-inhibition therapy, following recurrence after surgical interventions and chemotherapy. The patient was administered 31 cycles of 100 mg larotrectinib (Vitrakvi) twice daily. The patient remains stable with no evidence of local, nodal, or metastatic disease for more than three years following the initial presentation. This report aims to propose the use of larotrectinib as a management option for recurrent NTRK-positive cervical sarcomas.